Price To Earnings Ratio 17.50 | Sector PE 64.74 |
PB Ratio 4.15 | Sector PB 8.74 |
EPS 77.56 | Dividend Yield 1.00 |
Today's Volume 1.135 M | 5 Day Avg. Volume 1.215 M |
PEG Ratio 0.18 | Market Cap. ₹ 24,660.00 Cr. |
Time | NATCOPHARM | VS | Industry |
---|---|---|---|
1 Day | 1.25% | 0.62% | |
1 Week | -2.96% | -3.89% | |
1 Month | -1.48% | -7.55% | |
6 Months | 32.01% | 14.29% | |
1 Year | 89.06% | 48.6% |
Period (Days) | SMA | Indication |
---|---|---|
10 | 1377.91 | Bearish |
20 | 1353.7 | Bullish |
30 | 1368.84 | Bearish |
50 | 1404.59 | Bearish |
100 | 1404.13 | Bearish |
200 | 1219.62 | Bullish |
Annual | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |||||
---|---|---|---|---|---|---|---|---|---|
Operating Activities | 1211.60 | 849.10 | 46.50 | 298.80 | |||||
Investing Activities | -1032.70 | -477.10 | -5.30 | -103.30 | |||||
Financing Activities | -246.90 | -363.00 | 34.80 | -185.70 | |||||
Net Cash Flow | -68.00 | 9.00 | 76.00 | 9.80 |
All Figures in ₹ Cr., unless mentioned otherwise
Name | 1D (%) | 1W (%) | 1M (%) | 6M (%) | 1Y (%) |
---|---|---|---|---|---|
NATCO Pharma | 1.25 | -2.96 | -1.48 | 32.01 | 89.06 |
Alembic | -0.18 | -4.63 | -7.51 | -5.16 | -5.16 |
Aurobindo Pharma | 0.18 | -5.95 | -15.78 | -1.55 | 21.96 |
Fortis Healthcare | 3.93 | 3.49 | 6.33 | 32.1 | 72.46 |
Ajanta Pharmaceuticals | 1.43 | -2.7 | -14.64 | 8.27 | 45.89 |
Natco Pharma Limited is a vertically integrated R&D pharmaceutical company based in India. The company's field of activity is the pharmaceutical business, which includes research and development, production and sale of bulk drugs and ready-made medical preparations. The company produces ready-to-use dosage forms (FDFs), which it sells in India, the US and the rest of the world, and also produces active pharmaceutical ingredients (APIs). Its capabilities include multi-step synthesis, semi-synthetic splicing technologies, production of potent APIs and peptides. The company operates in two segments: Pharmaceuticals and Agricultural Chemicals. In the pharmaceutical industry, the Company channels its sales through FDFs and APIs. The agrochemicals segment focuses on specialty products, including pest control.